Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eczematous component in psoriasis is possibly a negative prognostic factor for deucravacitinib treatment outcome.

Dermatology (Basel, Switzerland)·2026
Same author

Ocular mucous membrane pemphigoid: A retrospective study.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Bimekizumab plus topical photochemotherapy effective in palmoplantar pustulosis in a patient with hidradenitis suppurativa.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2025
Same author

Origin of the inhomogeneous nanoscale resistivity in chromium doped V<sub>2</sub>O<sub>3</sub>.

Scientific reports·2025
Same author

Severe mixed hand and generalized eczema treated with the JAK inhibitor upadacitinib.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2024
Same author

Effective parallel evaluation of molecular design, expression and bioactivity of novel recombinant butyrylcholinesterase medical countermeasures.

Chemico-biological interactions·2024
Same journal

Mapping protein-DNA interactions across biological scales: principles, scalability and applications.

Methods (San Diego, Calif.)·2026
Same journal

Establishing a standard workflow for fluorescence-based nanoparticle tracking analysis for the reliable quantification of extracellular vesicles.

Methods (San Diego, Calif.)·2026
Same journal

Quantitative single-cell analysis of PML-RARα oncogene-induced DNA damage along cell cycle progression.

Methods (San Diego, Calif.)·2026
Same journal

Cilia SubQ: a modular suite of semi- and fully automated pipelines for analysis of primary cilia and ciliary subdomains.

Methods (San Diego, Calif.)·2026
Same journal

Projective invariant of surface ratio: application to pupil measurement through simulations and proof-of-concept recordings.

Methods (San Diego, Calif.)·2026
Same journal

A quantitative radiographic framework for longitudinal monitoring of additively manufactured biodegradable scaffolds with graded tantalum reinforcement.

Methods (San Diego, Calif.)·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Virus-like particle formulation optimization by miniaturized high-throughput screening.

Johannes Mohr1, Yap P Chuan, Yang Wu

  • 1The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, St Lucia, QLD 4072, Australia.

Methods (San Diego, Calif.)
|May 4, 2013
PubMed
Summary
This summary is machine-generated.

This study introduces a miniaturized high-throughput screening (MHTS) method for developing stable virus-like particle (VLP) vaccines. The MHTS approach rapidly identifies optimal formulations, accelerating vaccine development.

More Related Videos

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

Profiling of Surface Protein Epitopes on Viral Particles by Multiplex Dual-Reporter Strategy
08:07

Profiling of Surface Protein Epitopes on Viral Particles by Multiplex Dual-Reporter Strategy

Published on: January 12, 2024

Related Experiment Videos

Last Updated: May 11, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

Profiling of Surface Protein Epitopes on Viral Particles by Multiplex Dual-Reporter Strategy
08:07

Profiling of Surface Protein Epitopes on Viral Particles by Multiplex Dual-Reporter Strategy

Published on: January 12, 2024

Area of Science:

  • Biopharmaceutical development
  • Vaccine technology
  • Protein assembly characterization

Background:

  • Virus-like particles (VLPs) are promising vaccine candidates due to their immunogenicity and non-infectious nature.
  • VLP stability is critical for product viability, but comprehensive formulation studies are hindered by limited sample availability and low-throughput analytical methods.
  • Developing stable VLP formulations is essential for advancing vaccine candidates through the development pipeline.

Purpose of the Study:

  • To develop and validate a miniaturized high-throughput screening (MHTS) methodology for VLP formulation development.
  • To enable rapid screening of numerous formulation conditions using minimal sample quantities.
  • To identify optimal VLP formulations that enhance stability against aggregation, temperature, and freeze-thaw/drying processes.

Main Methods:

  • Integration of dynamic light scattering (DLS) and asymmetrical flow field-flow fractionation (AF4) in a formulation funnel analysis.
  • Utilized a DLS plate reader for rapid pre-screening of a wide range of formulations.
  • Employed AF4 for high-resolution analysis of promising VLP formulations identified by DLS.

Main Results:

  • The MHTS method successfully screened multiple stabilizers, including polysorbate 20, sucrose, trehalose, mannitol, and sorbitol.
  • Formulations with 0.5% polysorbate 20 and either 40% sucrose or 40% sorbitol stabilized VLPs at temperatures up to 58 °C.
  • A formulation of 40% sorbitol and 0.5% polysorbate 20 significantly improved VLP recovery after freeze-thawing (80% increase) and freeze-drying (50% increase).

Conclusions:

  • The presented MHTS strategy enables rapid exploration of VLP formulation space with reduced sample consumption.
  • This methodology maintains analytical resolution crucial for quality control in VLP product development.
  • The MHTS approach accelerates formulation development, potentially hastening the commercialization of VLP vaccines.